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Acute-phase serum amyloid A (SAA) is a family of acute-
phase proteins that have been evolutionarily conserved for 
approximately 500 million years (1, 2). Teleologically, this 
conservation suggests an important role for SAA in host 
defense. The precise functions of the SAA family have not 
been defined, although it is suggested that SAA has anti-
bacterial properties (3) and can serve as a chemoattractant 
for monocytes and neutrophils (4). SAA can also promote 
inflammation by inducing inflammatory cytokines, such as 
IL-1, TNF-, and IL-6, as well as metalloproteinases in 
smooth muscle cells and macrophages (5–9). SAA may act 
as a danger-associated molecular pattern molecule by inter-
acting with multiple pattern recognition receptors, such as 
Toll-like receptors, CD36, and FPRL1 (1). The pro-inflam-
matory functions of SAA should be seen in the context of 
recent data that SAA is an innate immune molecule capa-
ble of activating the NLR family pyrin domain containing 3 
(NLRP3) inflammasome, although the precise molecular 
events underlying this activation are not completely under-
stood (10–13). SAA has a strong association with cardiovas-
cular disease, where it can serve as a predictor of mortality 
(14). The key question is whether SAA serves as more than 
a marker, but rather as a mediator of acute vascular syn-
dromes (15).
The SAA family comprises at least four isoforms that 
likely arose from gene duplication. In humans, two SAA 
isoforms (SAA1 and SAA2) are highly induced during an 
acute-phase response, with plasma levels increasing up to 
1,000-fold or more. SAA1 and SAA2 are predominantly ex-
pressed in the liver, but also in extrahepatic tissues, and are 
found in plasma associated with HDL (16). The mouse ho-
mologs (SAA1.1 and SAA2.1) are similarly induced and 
share more than 90% amino acid identity (2). The SAA4 
isoform is an HDL-associated apolipoprotein that is 55% 
Abstract Serum amyloid A (SAA) is a family of acute-phase 
reactants. Plasma levels of human SAA1/SAA2 (mouse 
SAA1.1/2.1) can increase ≥1,000-fold during an acute-phase 
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SAA3 levels were 20% of SAA1.1/2.1 levels. Fast protein 
LC analyses indicated that virtually all of SAA1.1/2.1 eluted 
with HDL, whereas 15% of SAA3 was lipid poor/free. Af-
ter density gradient ultracentrifugation, isoelectric focusing 
demonstrated that 100% of plasma SAA1.1 was recovered 
in HDL compared with only 50% of SAA2.1 and 10% of 
SAA3. Thus, SAA3 appears to be more loosely associated 
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that SAA3 is a major hepatic acute-phase SAA in mice that 
may produce systemic effects during inflammation.—Tannock, 
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homologous to SAA1/2 and constitutively expressed at 
relatively low levels in both human and mouse liver. To 
date, no known immune or inflammatory activities have 
been ascribed to SAA4 (17, 18) and its function is largely 
unknown.
Mice express a third acute-phase SAA isoform, SAA3, 
which is not expressed in humans due to a premature stop 
codon in the human Saa3 gene (19). Mouse SAA3 is 69% 
homologous to SAA1.1/2.1 (2) and is induced in the liver 
as well as extrahepatic tissues (20), particularly adipocytes, 
and to a lesser extent in macrophages in inflammatory set-
tings. Prior studies have also reported SAA3 expression in 
testis, spleen, intestine, and kidney in acute inflammatory 
states (21), as well as in intestinal epithelial cells (22), lym-
phocytes, lymphoid follicles, and plasma cells of many nor-
mal tissues (23). In general, SAA3 is considered to be the 
“extrahepatic” SAA, exerting similar pro-inflammatory ac-
tivities in mouse macrophages (24) and adipose tissue (21, 
25) as human SAA1 and SAA2. Whether SAA3 contributes
to systemic SAA levels in mice has been the focus of a lim-
ited number of studies, with equivocal results. Whereas
SAA3 was determined to be a circulating SAA bound to
HDL in mice undergoing an acute inflammatory response
to lipopolysaccharaide (LPS) injection (24, 26), it was not
detected in HDL in plasma from ob/ob mice with chronic
low-grade inflammation (25). The goals of the present
study were to carefully define the degree to which SAA3
contributes to circulating SAA during an acute-phase re-
sponse, the extent to which SAA3 is associated with HDL,
and its cellular sources.
MATERIALS AND METHODS
Animals
C57BL/6 mice were obtained from Jackson Laboratory, Bar 
Harbor, ME. Mice deficient in SAA1.1 and SAA2.1 were bred to 
obtain a >99.9% C57BL/6 background (27). Mice deficient in 
SAA3 have been described (28). For simplicity, C57BL/6 mice, 
mice lacking SAA1.1/SAA2.1, and mice lacking SAA3 are referred 
to as SAA-WT, SAA1.1/2.1-DKO, and SAA3-KO, respectively. An 
acute-phase response was elicited by intraperitoneal injection of 
25 or 100 g LPS (Escherichia coli 0111:B4; Sigma Chemical Co.), 
then mice were humanely euthanized and plasma and tissue were 
obtained for analyses and preparation of HDL (LPS dose and du-
ration for each experiment are indicated in the figure legends). 
Control animals were not injected. All studies were performed 
with the approval of the University of Kentucky or University of 
Washington Institutional Animal Care and Use Committee.
Primary hepatocyte cultures
Primary hepatocytes were isolated from SAA-WT and SAA1.1/2.1-
DKO mice 6 h after injection with 25 g LPS using a two-step 
perfusion method (29). Briefly, the liver was first perfused with 
Ca+2/Mg+2-free HBSS containing 10 mM glucose, 10 mM HEPES, 
and 0.3 mM EDTA and then with HBSS containing 0.05% col-
lagenase type IV (C5138; Sigma), 1.3 mM CaCl2, 0.5 mM MgCl2, 
10 mM glucose, and 10 mM HEPES. Hepatocytes were washed 
by repeated low speed centrifugation (50 g for 2 min) and cell 
viability (normally 90–95%) was assessed by trypan blue exclusion. 
Cells were plated onto 12-well plates precoated with rat tail colla-
gen (354236; BD Biosciences, Bedford, MA) at a density of 
2 × 105 cells/well and cultured at 37°C under 5% CO2 in Williams’ 
Medium E (GIBCO) containing 10% fetal bovine serum (GIBCO), 
2% penicillin-streptomycin, 1% sodium pyruvate, 1% l-glutamine, 
and 1% insulin-transferrin-selenium (GIBCO). Cells were cul-
tured for 18 h after plating and then collected for RNA isolation.
RNA isolation and RT-PCR
Total RNA was isolated from mouse livers and hepatocytes us-
ing TRIzol reagent (Invitrogen) according to the manufacturer’s 
instructions. RNA from epididymal fat was isolated by RNeasy 
lipid tissue mini kit (7484; Qiagen). RNA samples (9 g) were 
treated with DNase 1 (TURBO DNA-free™ kit (AM1907; Invitro-
gen) for 30 min at 37°C. RNA from liver, epididymal fat (0.5 g), 
or cultured cells (0.1 g) was reverse transcribed into cDNA using 
the reverse transcription system (4368814; Applied Biosystems). 
After 4-fold dilution, 5 l were used as a template for real-time 
RT-PCR. Amplification was done for 40 cycles using Power SYBR 
Green PCR Master Mix kit (4367659; Applied Biosystems). Quan-
tification of mRNA was performed using the CT method and 
normalized to GAPDH for liver and hepatocytes or 36B4 for epi-
didymal fat. Primer sequences are as follows: GAPDH (accession 
number NM_008084) 5′-CTC ATG ACC ACA GTC CAT GCC 
A-3′, 5′-GGA TGA CCT TGC CCA CAG CCT T-3′; 36B4 (accession 
number NM_007475) 5′-AAG CGC GTC CTG GCA TTG TCT-3′,
5′-CCG CAG GGG CAG CAG TGG T-3′; SAA1.1/2/1 (accession
number NM_009117.3) 5′-CTC CTA TTA GCT CAG TAG GTT
GTG-3′, 5′-CAC TTC CAA GTT TCT GTT TAT TAC CC-3; SAA3
(accession number NM_011315.3) 5′-TTT CTC TTC CTG TTG
TTC CCA GTC-3′, 5′- TCA CAA GTA TTT ATT CAG CAC ATT
GGG A-3′.
Electrofocusing and immunochemical analysis
Aliquots of plasma (7 l) or HDL (13.5 g) isolated from LPS-
injected mice were subjected to isoelectric focusing (IEF), as pre-
viously described (26), using an Ampholine gradient consisting of 
20% (v/v) Ampholine (pH 3–10), 40% (v/v) Ampholine (pH 
4–6.5), and 40% (v/v) Ampholine (pH 7–9) (Pharmacia LKB Bio-
technology Inc.). Electrofocused samples were subjected to im-
munochemical analysis, as described (26). The SAA isoforms were 
identified by immunochemical staining utilizing rabbit anti-
mouse SAA antibody to identify SAA1.1 and SAA2.1 and rabbit 
anti-mouse SAA3 (a gift from Dr. Phillip Scherer, University of 
Texas Southwestern) to identify SAA3.
Plasma lipoprotein analysis and SAA measurement
Lipoproteins in 50 l of plasma pooled from six mice injected 
with 100 g LPS were separated by fast protein (FP)LC utilizing a 
Superose 6 column (17-5172-01; GE Healthcare, Uppsala, Swe-
den). The cholesterol content of 0.5 ml fractions was determined. 
SAA1.1/2.1 and SAA3 in plasma and FPLC fractions were deter-
mined by a mouse SAA ELISA kit (TP802M; Tridelta Develop-
ment Ltd., Ireland) and a mouse SAA3 ELISA kit (EZMSAA3-12K; 
EMD Millipore, Danvers, MA), respectively.
Mass spectrometric analysis
HDL from mice that were injected with 25 g LPS were sub-
jected to SDS-PAGE or IEF. Coomassie-stained bands correspond-
ing to the apparent molecular mass of SAA separated by SDS-PAGE 
(12 kDa) or the isoelectric point (pI) of SAA3 separated by 
IEF (9.2) were excised, washed, and subjected to in-gel trypsin 
digestion (30). The resulting tryptic peptides were extracted 
and subjected to LC-MS/MS using an LTQ Orbitrap Velos 
mass spectrometer (Thermo Scientific). The LC-MS/MS results 
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were searched against the mouse portion of the UniProt database 
using a local Mascot server (version 2.3; Matrix Science) for pro-
tein identification, including methionine oxidation and cyste-
ine carbamidomethylation as allowed side chain modifications. 
A false discovery rate of 1% was used in decoy search for the high-
confidence peptides. Proteins with a score of at least 30 for single 
high-confidence peptides were considered positive identifica-
tions. UniProt protein names and identifier numbers are used 
throughout this work.
Immunohistochemistry
Paraffin-embedded liver sections (8 m thick) were fixed in 
4% paraformaldehyde and incubated with 3% H2O2 for 10 min to 
quench endogenous peroxidases. After blocking endogenous bio-
tin using an avidin/biotin blocking kit (Vector Laboratories, Bur-
lingame, CA), slides were incubated overnight at 4°C with rabbit 
anti-mouse SAA (26) (1:2,000 dilution). Sections were subse-
quently incubated with biotinylated anti-rabbit IgG and avidin-
peroxidase according to the vendor’s instructions (Vectastain 
Elite ABC kit; Vector Laboratories). Immunoreactivity was visual-
ized using a DAB kit (K3468; Dako North America, Inc., Carpinteria, 
CA), followed by counterstaining with hematoxylin. Immunoreac-
tivity was visualized using the red chromogen, 3-amino-9-ethyl car-
bazole (Vector Laboratories). Images were captured on a Nikon 
ECLIPSE 80i microscope with the aid of NIS-Elements BR 4.00.08 
software.
In situ hybridization
In situ hybridization was performed essentially as described 
(31). For PCR amplification of liver cDNA, the following SAA 
gene-specific primers were used: murine SAA1.1/2.1 (NM_009117/
NM_011314) forward primer: 5′-ctcctattagctcagtaggttgtg-3′, re-
verse primer: 5′-cacttccaagtttctgtttattaccc-3′; and murine SAA3 
(NM_011315) forward primer: 5′-tttctcttcctgttgttcccagtc-3′, reverse 
primer: 5′-tcacaagtatttattcagcacattggg-3′. PCR was performed us-
ing 5 l cDNA in a total volume of 50 l containing 0.2 M primer 
mix, 1× PCR buffer, 3.0 mM MgCl2, 200 M dNTP mixture, and 
1 U GoTaq Flexi DNA polymerase (Promega) and the following 
program: 2 min at 95°C, 40 cycles at (45 s at 95°C, 45 s at 56°C, and 
45 s at 72°C), and a 10 min extension at 72°C. The PCR products 
were subcloned into pGEM-T (Promega) and their sequence iden-
tity was confirmed by double-stranded DNA sequencing. Plasmid 
constructs were linearized by SphI and NdeI for SAA1.1/2.1 and 
SAA3. Riboprobes in antisense and sense orientation were gener-
ated from linearized plasmid constructs by in vitro transcription 
using the appropriate RNA polymerases and 35S-UTP in a volume 
of 10 l containing 1 g of linearized plasmids. After 90 min incu-
bation at 37°C, 10 U of RNase-free DNase I were added to the reac-
tions and incubated for another 15 min. After adding RNase-free 
water to 20 l and 20 l sodium carbonate buffer [80 mM NaHCO3 
and 120 mM Na2CO3 (pH 10.2)] for limited hydrolysis, the reac-
tion was incubated at 60°C for the appropriate time [t = (Lo – 
Lf)/K × Lo × Lf, where Lo is the cDNA length, Lf is the expected 
length of the probes (i.e., 250 bp), and K is 0.11], as described 
(31). The reaction was stopped by adding 2 l of 10% acetic acid. 
The probes were purified using Micro Bio-Spin P-30 columns (Bio-
Rad). For in situ hybridization histochemistry, frozen 8 m-thick 
liver sections were fixed in 4% paraformaldehyde for 60 min. After 
three washes in PBS and incubation in 0.4% Triton X-100 for 10 
min, the slides were rinsed in deionized water and transferred to 
0.1 M triethanolamine (pH 8.0). After 1 min incubation, acetic 
anhydride was added under strong stirring to a final concentration 
of 0.25% (v/v) and further incubated for 10 min. The slides were 
washed for 10 min in PBS and rinsed in deionized water prior to 
dehydration in 50% and 70% ethanol. Radioactive probes were 
diluted to 5 × 104 dpm/l in hybridization solution [600 mM 
NaCl, 10 mM Tris-HCl (pH 7.5), 1 mM EDTA-Na2, 0.05% tRNA, 20 
mM dithiothreitol, 1× Denhardt’s solution, 10% dextran sulfate, 
100 g/ml sonicated salmon sperm DNA, and 50% formamide]. 
Prehybridized sections were incubated with 100 l hybridization 
solution containing radioactive RNA probes at 60°C in a for-
mamide humid chamber box for 16 h. After a series of washes, the 
sections were dehydrated in 50% and 70% ethanol. For autoradio-
graphic detection, slides were coated with Kodak NTB-2 nuclear 
emulsion (Eastman Kodak, Rochester, NY) and exposed at 4°C for 
5–30 days in the dark. Slides were developed in Kodak D19 solu-
tion and counterstained with cresyl violet. Photographic documen-
tation was performed under bright-field illumination using a 
Nikon ECLIPSE 55i microscope with the aid of NIS-Elements BR 
4.13.04 software.
Statistical analysis
Data are expressed as mean ± SD. Results for Figs. 2 and 3B 
were analyzed by one-way ANOVA followed by a Bonferroni post-
test. Statistical analysis for Fig. 4D was performed using the two-
tailed Student’s t-test for unpaired data. P < 0.05 was considered 
statistically significant. All statistical analyses were carried out us-
ing GraphPad Prism 5.
RESULTS
SAA1.1/2.1 and SAA3 expression in mouse liver
The classical murine acute-phase reactants, SAA1.1 and 
SAA2.1, are expressed primarily in the livers of mice and 
are dramatically upregulated following an inflammatory 
stimulus (20). In contrast to SAA1.1 and SAA2.1, SAA3 is 
generally thought to be mainly expressed extra-hepatically, 
predominantly by adipocytes, but also by macrophages 
(21, 24). However, the relative expression of the various 
mouse acute-phase SAA isoforms in tissues and plasma has 
not been adequately documented, partly due to the lack of 
validated reagents that distinguish SAA1.1/2.1 and SAA3. 
The recent development of mice deficient in SAA1.1/2.1 
(27) or SAA3 (28) allowed us to confirm the isoform speci-
ficity of the reagents used in our study to distinguish SAA3
from the other two acute-phase SAA isoforms. As expected,
SAA1.1/2.1 mRNA was readily detected by RT-PCR in the
liver of a mouse injected with LPS, but not a control mouse
liver (Fig. 1A). Notably, SAA3 mRNA appeared to be simi-
larly induced by LPS in SAA-WT mouse liver. The specific-
ity of the primers used to amplify SAA1.1/2.1 and SAA3
cDNAs was demonstrated by the absence of RT-PCR prod-
ucts in LPS-injected SAA1.1/2.1-DKO and SAA3-KO mouse 
livers, respectively (Fig. 1A).
It was of interest to determine whether SAA3 expressed 
in acute-phase mouse liver was due to induction in hepato-
cytes or other hepatic cell types, such as resident macro-
phages. As a first approach to address this question, primary 
hepatocytes were isolated from SAA-WT and SAA1.1/2.1-
DKO mice 6 h after injection with 25 g LPS, and then 
cultured for 18 h prior to RNA isolation. Results from 
RT-PCR indicated that hepatocytes were induced to express 
SAA3 during an acute-phase response (Fig. 1A). We next 
performed in situ hybridization as another approach to 
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investigate which cell type(s) express SAA3 mRNA in 
acute-phase mouse liver (Fig. 1B). Cresyl violet-stained 
liver sections showed dense signals for SAA mRNA in liver 
sections of LPS-injected SAA-WT mice, but not PBS-injected 
mice (Fig. 1B). Control experiments using sense-strand ri-
boprobes demonstrated the specificity of the hybridiza-
tion signals (inserts on right panels, Fig. 1B). Moreover, the 
broad distribution of the hybridization signal throughout 
the tissue section suggested that SAA3 mRNA expression is 
not limited to resident macrophages (i.e., Kuppfer cells) in 
acute-phase mouse liver, and that hepatocytes are likely an 
important source of SAA3 expressed in the liver during an 
inflammatory response. This conclusion was supported by 
results from immunohistochemical staining using a poly-
clonal anti-SAA antibody (Fig. 1C). As expected, robust 
staining for SAA was observed in liver sections from LPS-
injected SAA-WT mice, with a tissue distribution consistent 
with expression by hepatocytes. Similarly distributed im-
munopositive staining was also evident in liver sections 
of an LPS-injected SAA1.1/2.1-DKO mouse, albeit at less 
intensity compared with staining in LPS-injected SAA-WT 
mice. Immunoreactivity was negligible in control SAA-WT 
and SAA1.1/2.1-DKO mouse liver, strongly suggesting that 
the signal observed in LPS-injected SAA1.1/2.1-DKO 
mouse liver represents SAA3. Moreover, the diffuse immu-
nopositive staining for SAA1.1/2.1-DKO sections stained 
Fig. 1. SAA 1.1/2.1 and SAA3 in mouse liver. A: Total RNA was isolated from the livers of noninjected SAA-WT mice, and SAA-WT, 
SAA1.1/2.1-DKO, and SAA3-KO mice injected with 100 g LPS, as well as primary hepatocytes isolated from SAA-WT and SAA1.1/2.1-DKO 
mice injected with 25 g LPS or PBS, as indicated. RT-PCR was performed using primers specific for SAA3 and SAA1.1/2.1. B: High-resolu-
tion bright-field images of emulsion-coated liver sections from PBS- or LPS-injected SAA-WT mice hybridized with SAA3- or SAA1.1/2.1-anti-
sense probes. Inserts in the right-hand panels represent hybridization of SAA3- or SAA1.1/2.1-sense probes to liver sections of an LPS-injected 
SAA-WT mouse. Magnification, 40×; scale bar, 20 M; exposure times, 5 days for SAA1.1/2.1 and 30 days for SAA3. C: Immunostaining of 
liver sections from a SAA-WT or SAA1.1/2.1-DKO mice injected with either PBS or LPS (25 g), as indicated, using antibodies that detect 
SAA1.1/2.1 and SAA3 (anti-SAA) or macrophages (anti-F4/80). Images were photographed under 20× objective magnification (scale bar, 50 
M). Arrows in the right panels indicate immunopositive staining for F4/80 (red/brown chromogen).
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with anti-SAA was distinct from the signal observed for anti-
F4/80, indicating that Kupffer cells are not likely to be the 
only source of SAA3 in mouse liver (Fig. 1C). Taken to-
gether, our data indicate that SAA3 is a highly inducible 
acute-phase reactant in mouse hepatocytes.
SAA1.1/2.1 and SAA3 expression in mouse adipose tissue
To address the widely held concept that SAA3 is the pre-
dominant isoform expressed in extra-hepatic tissues, we 
next determined the extent to which each of the three 
acute-phase SAA isoforms were induced above baseline in 
liver and epididymal fat of mice 19 h after injection with 
100 g LPS (Fig. 2). The values for LPS-treated mice are 
shown relative to those of control (non-LPS injected) SAA-
WT mice, which were arbitrarily given a value of 1. SAA3 
and SAA1.1/2.1 expression was significantly upregulated 
in the livers of LPS-treated SAA-WT mice (P = 0.0004 and 
P < 0.0001, respectively), and not detected in their corre-
sponding LPS-treated KO controls. The increase in ex-
pression of SAA3 (2,500-fold) was somewhat less robust 
compared with SAA1.1/2.1 (6,000-fold). In contrast to 
liver, SAA3 was the more inducible SAA in epididymal fat, 
increasing 400-fold in epididymal fat of LPS-treated SAA-
WT (P = 0.0002), compared with 100-fold induction of 
SAA1.1/2.1 (P = 0.047). Thus, while SAA3 appears to be a 
major SAA isoform in fat during inflammation, its expres-
sion in adipose tissue appears to be greatly overshadowed 
by a much more robust induction of SAA3 in hepatocytes.
SAA3 protein in plasma
According to a previous report, SAA3 is induced in adi-
pose tissue of obese mice, but is not detected on circulating 
HDL (25). Thus, it was of interest to determine whether 
SAA3 is present in plasma of mice undergoing an acute-
phase response. Plasma was collected from untreated 
SAA-WT mice and SAA-WT and SAA3-KO mice after LPS 
injection and separated by IEF. The Ampholine gradient 
for IEF was optimized to maximize the separation of SAA1.1 
(pI 6.3), SAA2.1 (pI 6.45), and the more basic SAA3 
(pI 9.2) (26). This technique confirmed the presence of 
SAA1.1/2.1 in the plasma of LPS-treated SAA-WT and 
SAA3-KO mice, but not in the plasma of untreated SAA-WT 
mice (Fig. 3A). An immunopositive band that migrated at 
the expected pI of SAA3 was also detected in LPS-injected 
SAA-WT mice, but not in SAA3-KO mice or untreated SAA-
WT mice (Fig. 3A). The relative plasma concentrations of 
SAA isoforms in acute-phase SAA-WT mice were estimated 
by ELISA using two commercially available kits that were 
confirmed to be specific for either SAA1.1/2.1 or SAA3 us-
ing plasma from LPS-treated SAA1.1/2.1-DKO and SAA3-
KO mice, respectively (Fig. 3B). Based on these assays, 
plasma SAA3 concentrations (2.5 mg/ml) corresponded 
to 20% of plasma SAA1.1/2.1 (12.0 mg/ml) in acute-
phase mouse plasma.
SAA3 association with HDL
It is well-established that the vast majority of SAA1.1/2.1 
in plasma is associated with HDL. SAA3 has also been re-
ported to be on the HDL fraction after LPS injection 
(24, 26), but not in obese mice (25). To directly address 
whether there are differences in SAA1.1/2.1 and SAA3 as-
sociation with HDL, plasma from LPS-injected SAA-WT mice 
was separated by FPLC and fractions were analyzed for SAA 
content. As expected, virtually all of the SAA1.1/SAA2.1 
eluted in HDL-containing fractions (Fig. 4A). Interestingly, 
whereas the majority of plasma SAA3 was associated with 
the HDL peak, 15% eluted in fractions beyond the HDL 
peak (Fig. 4B), suggesting a portion of plasma SAA3 exists 
in a lipid-poor or lipid-free form. To investigate this finding 
further, HDL was isolated from acute-phase SAA-WT mouse 
plasma by density gradient ultracentrifugation and aliquots 
were subjected to SDS-PAGE or IEF. LC-MS/MS analysis of 
Coomassie-stained bands corresponding to acute-phase 
SAAs on SDS-PAGE (12 kDa) and SAA3 on IEF (pI 9.2) 
confirmed that the isolated HDL fraction did indeed con-
tain SAA3 (data not shown). However, the recovery of each 
of the SAA isoforms during the ultracentrifugation steps 
was different, as evident in the results presented in Fig. 4C, 
D. For this experiment, aliquots of acute-phase plasma and
HDL isolated from the plasma (d 1.063–1.21) were applied
to an IEF gel and then immunoblotted; the amount of HDL
analyzed was calculated to match the HDL-cholesterol in
electrofocused plasma (Fig. 4C, D). Interestingly, based on
Fig. 2. SAA 1.1/2.1 and SAA3 expression in mouse liver and adi-
pose tissue. Semi-quantitative RT-PCR using isoform-specific prim-
ers was performed using cDNA prepared from 0.5 g liver RNA 
(top panel) and 0.5 g epididymal fat RNA (bottom panel), iso-
lated from control SAA-WT or LPS-injected (100 g LPS) SAA-WT, 
SAA1.1/2.1-KO, and SAA3-KO mice. Values are the mean ± SD, 
n = 3–6. *P < 0.05; ***P < 0.001; ****P < 0.0001.
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this analysis, there appeared to be a selective loss of SAA2.1 
and even greater loss of SAA3 in the isolated acute-phase 
HDL preparations compared with plasma, suggesting dis-
sociation of SAA2.1 and, to a greater extent, SAA3 from 
HDL during ultracentrifugal isolation.
DISCUSSION
The mouse is a widely utilized animal model to investi-
gate the pathogenic role of SAA in chronic diseases. The 
human Saa1 and Saa2 and the mouse Saa1.1 and Saa2.1 
genes are thought to be evolutionary homologs based on 
their sequence conservation, relative map positions, and 
transcriptional orientations (2). Mouse SAA3 shares 69% 
amino acid identity with human SAA1 (2), the major hu-
man SAA isoform expressed in the liver and extrahepatic 
tissues, including adipocytes (32). However, Saa3 is a pseu-
dogene in humans (19), which has limited the interest in 
studying SAA3 biology in mice. Moreover, given a prior 
publication indicating that adipocyte-derived SAA3 from 
ob/ob mice, which are characterized by chronic low grade 
inflammation, does not circulate (25), it has been sug-
gested that SAA3 exerts only localized effects in tissues and 
does not represent a systemic acute-phase SAA (28, 33). 
Results from the current study in which stimulation of 
SAA3 was more intense as a result of LPS injection indicate 
that the role of SAA3 in acute systemic inflammation in 
mice should be reassessed. We show that SAA3 is a hepato-
cyte-expressed acute-phase reactant that comprises a sub-
stantial portion (15–20%) of the total plasma SAA in 
endotoxemic mice. Unlike SAA1.1/2.1, the other acute-
phase mouse SAAs, a portion of plasma SAA3 is present in 
a lipid-poor form, not associated with HDL. These findings 
may have important implications for previous studies of 
SAA in mice that focused only on SAA1.1/2.1.
Our data, in which an acute-phase response was induced 
by the injection of LPS, contrast with previous studies that 
failed to detect SAA3 in the circulation during a chronic 
low-grade inflammatory response due to obesity (25). 
Thus, it is likely that the discrepant findings are due to vari-
ations in the ability of different inflammatory stimuli to in-
duce SAA3. For example, it was previously published that 
casein injection was relatively ineffective in inducing SAA3 
in livers of mice compared with SAA1.1/2.1 (20). In an-
other study, the conclusion that SAA3 is not a circulating 
acute-phase SAA was based on mass spectrometric analysis 
of HDL isolated by sequential density ultracentrifugation 
from mice in which SAA3 was relatively mildly induced by 
obesity (25). Our data indicate that a portion of plasma 
SAA3 (15%) is not associated with HDL, and that the 
bulk of HDL-associated SAA3 is stripped off the particle 
during ultracentrifugation. Although the relative recovery 
of plasma SAA2.1 was also lower compared with SAA1.1 
during HDL isolation, we were unable to detect lipid-poor 
SAA2.1 in acute-phase mouse plasma. Thus, our study indi-
cates that SAA3 is a major acute-phase SAA isoform that 
differs from SAA 1.1/2.1 in that it seems to be more loosely 
associated with HDL. Differences in the sequence of the 
hydrophobic N terminus, the lipid associating domain of 
SAA, may account for differences in HDL association for 
SAA1.1/2.1 and SAA3 (34).
The designation of SAA3 as the extrahepatic SAA ap-
pears to be a misnomer, given that the induction of Saa3 in 
mouse liver after LPS injection (2,500-fold) is of the same 
order of magnitude as Saa1.1/2.1 (6,000-fold). Because 
our oligonucleotide primers do not distinguish SAA1.1 
and SAA2.1 mRNAs, RT-PCR quantification reflects the to-
tal abundance of both transcripts. Thus, it appears that the 
Saa1.1, Saa2.1, and Saa3 genes may be similarly induced in 
hepatocytes during an acute-phase response. Interestingly, 
the total amount of SAA1.1 and SAA2.1 protein detected in 
the plasma exceeded the amount of SAA3 by 5-fold. The 
modest discrepancy in mRNA and protein data may reflect 
ambiguities in assays, posttranscriptional differences in ex-
pression or secretion of the different SAA isoforms, or the 
Fig. 3. SAA protein in plasma. A. SAA isoforms in plasma of untreated SAA-WT and LPS-injected (100 g LPS) SAA-WT and SAA3-KO 
mice were separated by IEF utilizing an Ampholine gradient, as described in the Materials and Methods, and pressure-blotted onto nitrocel-
lulose. The SAA isoforms were identified by immunochemical staining utilizing rabbit anti-mouse SAA antibody to identify SAA1.1 and 
SAA2.1 (a) and rabbit anti-mouse SAA3 to identify SAA3 (b). B: SAA3 and SAA1.1/2.1 in the plasma of control SAA-WT and LPS-injected 
(100 g LPS) SAA-WT, SAA3-KO, and SAA1.1/2.1-DKO mice were measured by ELISA utilizing kits specific for the mouse SAA isoforms. 
Values are the mean ± SD, n = 3–6. ****P < 0.0001.
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susceptibility of lipid-poor SAA3 to be more rapidly cleared 
from the plasma. Whether SAA3 expressed in adipose or 
other extrahepatic tissues contributes to circulating SAA 
was not specifically addressed in this study. Our data are in 
agreement with other reports that SAA3 is more highly in-
duced in adipose tissue compared with SAA1.1/2.1 (33). 
Nevertheless, it seems unlikely that adipose tissue-derived 
SAA3 makes a major contribution to total systemic SAA 
in endotoxemic mice, given the relative fold induction 
of SAA3 mRNA in fat (400-fold) compared with liver 
(2,500-fold).
The relative ability of different SAA isoforms to dissoci-
ate from HDL could hold functional implications. We and 
others previously reported that HDL-associated SAA, un-
like lipid-poor SAA, does not activate pro-inflammatory 
signaling pathways (7, 35–37). Thus, in order to exert in-
flammatory effects, liver-derived SAA must dissociate from 
HDL in tissues. The mechanism by which this occurs is un-
known, but may be mediated by interactions with proteo-
glycans, which are known to be involved in SAA deposition 
into amyloid fibrils (38, 39). Whether SAA3 may be par-
ticularly biologically active in vivo due to a higher propen-
sity to spontaneously disassociate from HDL merits further 
study. Moreover, the respective contributions of hepatocyte-
produced SAA (presumably associated with HDL) versus 
SAA derived from extrahepatic tissues (likely present in a 
lipid-poor form) in promoting inflammation also needs to 
be explored. As noted above, 15% of circulating SAA3 
(2–3% of total SAA) in plasma of LPS-injected mice ap-
pears to be present in a lipid-poor form. Whether this 
minor component reflects SAA3 produced by extrahepatic 
tissues is not known, but it is notable that the fold-induction 
of SAA3 mRNA in adipose tissue corresponds to 15–20% 
of the fold-induction of SAA3 mRNA in the liver after LPS 
injection. It is possible that extrahepatic SAA (i.e., adipocyte- 
or macrophage-derived) produces inflammatory effects 
more potently than the abundant systemic SAA present on 
HDL particles. On the other hand, it is conceivable that 
HDL particles readily access extravascular spaces at sites of 
infection or tissue injury, and that SAA can be stripped off 
HDL to exert its biological actions.
As an innate immune molecule, SAA has been suggested 
to play a role in a significant number of chronic inflamma-
tory diseases, including rheumatoid arthritis, cardiovascu-
lar disease, obesity, pulmonary diseases, and cancer (18). 
SAA has been shown to be a predictor of clinical outcomes 
Fig. 4. SAA3 association with HDL. Pooled plasma from six SAA-WT mice injected with 100 g LPS was separated by FPLC and the total 
cholesterol (TC) content of eluted fractions was measured to determine the lipoprotein profile (y axis of panels A and B). The SAA1.1/2.1 
content of FPLC fractions (A) and SAA3 content of FPLC fractions (B) were measured by isoform-specific ELISAs. C: HDL (d 1.063–1.21) was 
isolated by sequential density gradient ultracentrifugation from the plasma of SAA-WT mice injected with 25 g LPS. Aliquots of plasma (7 l) 
and HDL (13.5 g) were subjected to IEF utilizing an Ampholine gradient, as described in the Materials and Methods, to separate the SAA 
isoforms, followed by pressure-blotting onto nitrocellulose. Equivalent amounts of HDL-cholesterol were loaded in each lane. SAA1.1 and 
SAA2.1 were detected with a rabbit anti-SAA antibody (a) and SAA3 was detected by an anti-mouse SAA3 antibody (gift of Dr. Phillip Scherer, 
University of Texas Southwestern) (b). D: Immunopositive bands from C were quantified by densitometric scanning and the values for isolated 
HDL were expressed relative to the corresponding values for plasma, which were arbitrarily given a value of 1. **P < 0.01, ***P < 0.001.
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in patients with acute coronary syndromes (14, 40, 41). 
Whether SAA plays a direct role in the pathogenesis of 
chronic inflammatory diseases, or is merely a marker of in-
creased risk, has been the topic of intense investigations 
over the past several decades, and the recent development 
of mouse strains with altered SAA gene expression have 
provided important new insights. For example, we and oth-
ers reported increased atherosclerosis development in 
apoE/ mice overexpressing SAA1 (42, 43). However, de-
ficiency of SAA1.1/2.1 has been shown to have no, or only 
modest, effects on atherosclerotic lipid deposition in 
apoE/ and LDL receptor/ mice, respectively (44, 45). 
The paradoxical findings may be due to the fact that the 
previous loss-of-function studies did not take into account 
the potential role of SAA3 in mouse atherosclerosis mod-
els. We recently determined that overexpression of SAA3 
using an adeno-associated viral vector in apoE/ mice 
resulted in a significant 4-fold increase in atherosclerosis 
lesion area compared with control apoE/ mice, whereas 
anti-sense oligonucleotide-mediated suppression of SAA3 
decreased atherosclerosis in apoE/ mice deficient in 
SAA1.1/2.1 (46). On the other hand, recent studies from 
our laboratory determined that apoE/ mice deficient in 
only SAA1.1/2.1 are protected from angiotensin II-induced 
abdominal aortic aneurysm (AAA) formation, suggesting a 
minor role for SAA3 in experimental AAA (6). In general, 
there is a lack of studies to address whether there are func-
tional differences in SAA1.1, SAA2.1, and SAA3. Mouse 
SAA1.1 and SAA2.1 and human SAA1 and SAA2 are highly 
homologous (90% amino acid conservation) and coordi-
nately regulated in cells, leading to the assumption that 
they are functionally redundant. However, differences in 
function have been identified. Most notably, SAA1/SAA1.1, 
and not SAA2/SAA2.1, has a propensity to be deposited 
extracellularly as insoluble amyloid fibrils (26). Modest 
differences in the capacity to promote cellular cholesterol 
efflux and interact with pattern recognition receptors have 
also been noted for SAA1.1 and SAA2.1 (47). Based on 
available data, it appears that SAA3 shares activities similar 
to SAA1.1/2.1, although more studies are needed. As 
noted above, our finding that lipid-poor SAA3 is present 
in plasma during the acute-phase response may have im-
portant functional implications. Several researchers have 
pointed to SAA’s ability to induce matrix-degrading en-
zymes as a central mechanism underlying its pathogenic 
effects in chronic inflammatory disease. In patients with 
rheumatoid arthritis or psoriatic arthritis, SAA induces 
matrix metalloproteinase in synovial fibroblasts and is as-
sociated with increased joint destruction (48). Similarly, 
SAA1.1/2.1 induces matrix metalloproteinases in the aor-
tic vascular wall in a mouse model of angiotensin II-induced 
AAA formation (6). These data could suggest an explana-
tion why the evolutionarily conserved pro-inflammatory 
SAA is beneficial in the innate immune context: by lessen-
ing connective tissue tension to promote cellular diapede-
sis and even accommodate edema formation. However, in 
“modern” chronic inflammatory diseases, this innate ben-
eficial function can contribute to progression by negatively 
impacting connective tissue integrity.
In summary, these studies shed light on the previous mis-
conceptions that mouse SAA3 is an extrahepatic SAA. 
Moreover, we show that SAA3 is present in the circulation 
bound to HDL. Unlike SAA1.1/2.1, a portion of SAA3 in 
plasma is present in a lipid-free form, a distinct feature that 
may have important functional implications. Additional 
studies are needed to address the respective activities of the 
acute-phase mouse SAAs, and how these activities relate to 
the human SAA isoforms. Ignoring SAA3 in mouse models 
of chronic inflammatory diseases may confound interpre-
tation.
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